Replimune Group, Inc.

Ownership Transactions Reported by 22 Insiders

Symbol
REPL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
500 Unicorn Park, Woburn, MA

Insiders trading volume in the past year

Replimune Group, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Omega Fund IV, L.P. 10%+ Owner $103M Mar 14, 2022
Philip Astley-Sparke Executive Chairman, Director $14.6M -$245K -1.65% Aug 30, 2024
Robert Coffin Director $11.8M -$74.2K -0.63% May 16, 2024
Colin Love Chief Operating Officer $5.03M -$114K -2.22% May 16, 2024
Pamela Esposito Chief Business Officer $2.88M Sep 11, 2023
Tanya Lewis Chief Dev. Op. Officer $1.48M Jun 13, 2023
Jean Franchi Chief Financial Officer $1.41M May 16, 2023
Sushil Patel Chief Executive Officer, Director $1.37M -$131K -8.7% May 16, 2024
Emily Luisa Hill Chief Financial Officer $1.03M -$91K -8.13% Aug 16, 2024
Konstantinos Xynos Chief Medical Officer $878K -$240K -21.5% Jun 7, 2024
Christopher Sarchi Chief Commercial Officer $597K -$71.7K -10.7% May 16, 2024
Andrew Schwendenman Chief Accounting Officer $247K -$14.9K -5.67% May 16, 2024
Kapil Dhingra Director Apr 1, 2024
Paolo Pucci Director Apr 1, 2024
Christy J. Oliger Director Apr 1, 2024
Jason P. Rhodes Director Apr 1, 2022
Hyam Levitsky Director Apr 1, 2024
Hugo Alexander Slootweg Director Apr 1, 2023
Dieter Weinand Director Apr 1, 2024
Veleka Peeples-Dyer Director Apr 1, 2024
Joseph P. Slattery Director Apr 1, 2024
Madhavan Balachandran Director Sep 4, 2024

Recent Insider Transactions by Companies or Individuals for Replimune Group, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.